$ISIS Recent News 5 companies that will benefit from

New Post Public Reply Private Reply Replies (0) Message Board

Aug 31, 2014 at 12:42 PM

$ISIS Recent News

5 companies that will benefit from ALS awareness 7:58 a.m. Aug. 22, 2014 - Jennifer Booton
Investors blow on the dice as Iraq and the Fed shake up markets 9:09 a.m. June 16, 2014 - Shawn Langlois
S&P, Dow pull in from latest record highs 11:10 a.m. June 2, 2014 - Michael Ashbaugh
Health-care-related stocks keep on giving 1:02 p.m. Feb. 12, 2014 - The Trading Deck
See the future 1:42 p.m. Feb. 3, 2014 - Cody Willard
Charting the S&P 500’s excellent 2013 adventure 12:59 p.m. Dec. 23, 2013 - Michael Ashbaugh
Market technicals tame despite debt-ceiling debate 11:43 a.m. Sept. 25, 2013 - Michael Ashbaugh
Isis reaches a new high on tests for treatment of muscular disorder 3:03 p.m. Sept. 19, 2013 - Russ Britt
Isis, Biogen working on ways to fight disease through gene altering 10:59 a.m. Sept. 9, 2013 - Russ Britt
Isis, Novartis, Halozyme all rise on positive product news 11:48 a.m. Sept. 3, 2013 - Russ Britt
Despite positive tests, investors let some air out of Isis Pharmaceuticals 11:30 a.m. July 22, 2013 - Russ Britt
5 stocks to watch 3:35 p.m. July 11, 2013 - The Trading Deck
Onyx share surge lifts several boats in biotech harbor, including ETFs 11:33 a.m. July 1, 2013 - Russ Britt
S&P’s 50-day average marks the technical test 11:39 a.m. June 27, 2013 - Michael Ashbaugh
After the close: Alexion climbs on FDA news, Biogen basks in glory 5:35 p.m. June 26, 2013 - Russ Britt
After dramatic moves, Isis and Allergan dart in different directions 6:18 p.m. June 25, 2013 - Russ Britt
Dissecting the close: Isis soars on data, while Pfizer loses on spin-off 7:26 p.m. June 24, 2013 - Russ Britt
3 ways to play the biotech boom 7:01 a.m. June 3, 2013 - Jeff Reeves
S&P 500 holds the 50-day average — barely 11:41 a.m. April 18, 2013 - Michael Ashbaugh
Biogen inks drug-development deal with Isis 3:06 p.m. Dec. 10, 2012 - MarketWatch.com

Isis Pharmaceuticals Starts Phase III Study on ISIS-APOCIIIRx - Analyst Blog 4:55 p.m. Aug. 29, 2014 - Zacks.com
Biotech Stocks 101 — What Investors Need to Know 6:59 a.m. Aug. 29, 2014 - InvestorPlace.com
Hottest Healthcare Stocks Now – LCI ISIS CNC ACHN 8:00 a.m. Aug. 28, 2014 - InvestorPlace.com
Companies With 'ISIS' Name Get Unwanted Attention 3:06 p.m. Aug. 27, 2014 - FOXBusiness
Isis Pharmaceuticals, Inc. (ISIS) Surges: Stock Moves 10.8% Higher - Tale of the Tape 9:11 a.m. Aug. 27, 2014 - Zacks.com
CNBC's Stock Pops & Drops From August 26 7:16 p.m. Aug. 26, 2014 - benzinga.com
Biggest Movers in Healthcare Stocks Now – ISIS THRX EXAS CBPO 6:00 a.m. Aug. 26, 2014 - InvestorPlace.com
Fast Money Picks For August 26 7:03 p.m. Aug. 25, 2014 - benzinga.com
Hottest Healthcare Stocks Now – PBYI ISIS EXAS IMGN 8:30 a.m. Aug. 25, 2014 - InvestorPlace.com
Hottest Healthcare Stocks Now – PRGO WX ISIS TARO 8:30 a.m. Aug. 14, 2014 - InvestorPlace.com
UPDATE: Laidlow & Co. Initiates Coverage on Isis Pharmaceuticals, Inc. at Buy, Announces $52.00 PT 10:34 a.m. Aug. 12, 2014 - benzinga.com
Alnylam Pharmaceuticals Has Plenty On Its Plate 10:36 a.m. Aug. 9, 2014 - Seeking Alpha
Isis Pharmaceuticals Posts Narrower-Than-Expected Q2 Loss - Analyst Blog 9:10 a.m. Aug. 7, 2014 - Zacks.com
Isis Pharmaceuticals, Inc. (ISIS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. Aug. 7, 2014 - Zacks.com
Biggest Movers in Healthcare Stocks Now – CBPO ISIS HAE LPNT 2:00 p.m. Aug. 5, 2014 - InvestorPlace.com
Company News for August 05, 2014 - Corporate Summary 10:10 a.m. Aug. 5, 2014 - Zacks.com
ISIS Pharmaceuticals' (ISIS) CEO Stan Crooke on Q2 2014 Results - Earnings Call Transcript 4:24 p.m. Aug. 4, 2014 - Seeking Alpha
10-Q: ISIS PHARMACEUTICALS INC 3:29 p.m. Aug. 4, 2014 - Edgar Online - (EDG = 10Q, 10K)
Biggest Movers in Healthcare Stocks Now – ALNY ISIS INCY HTWR 1:15 p.m. Aug. 4, 2014 - InvestorPlace.com
Insider Trading Alert - GPN, UHS And ISIS Traded By Insiders 10:30 a.m. Aug. 4, 2014 - TheStreet.com

Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS 7:00 a.m. Aug. 28, 2014 - PR Newswire - PRF
Orphan Diseases Partnering Terms and Agreements 9:10 p.m. Aug. 27, 2014 - PR Newswire - PRF
Critical Alerts For Arrowhead Research, Isis Pharmaceuticals, MobileIron, JP Morgan Chase and Viacom Released By InvestorsObserver 9:31 a.m. Aug. 27, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy 7:00 a.m. Aug. 15, 2014 - PR Newswire - PRF
Expert Briefing on Biotech Stocks -- Nanosphere, Vanda Pharma, Synta Pharma, Halozyme Therapeutics, and Isis Pharma 9:30 a.m. Aug. 14, 2014 - PR Newswire - PRF
Critical Alerts For Stratasys, Horizon Pharma, Isis Pharmaceuticals, Amgen, and Discover Financial Services Released By InvestorsObserver 9:31 a.m. Aug. 8, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 7:00 a.m. Aug. 1, 2014 - PR Newswire - PRF
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 7:00 a.m. July 28, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a) 7:00 a.m. July 17, 2014 - PR Newswire - PRF
Critical Alerts For Cninsure, Freeport-McMoRan, Level 3 Communications, Electronic Arts, and Isis Pharmaceuticals Released By InvestorsObserver 9:31 a.m. July 16, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx 7:00 a.m. July 16, 2014 - PR Newswire - PRF
Type 2 Diabetes Global Clinical Trials Review, H1, 2014 3:31 p.m. July 15, 2014 - PR Newswire - PRF
Biotech Equities Technical Momentum -- Research on Organovo, Prana Biotechnology, Isis Pharma, and Pharmacyclics 7:04 a.m. July 14, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program 7:00 a.m. July 2, 2014 - PR Newswire - PRF
Critical Alerts For General Electric, Deere, Isis Pharmaceuticals, Expedia, and Sears Holdings Released By InvestorsObserver 9:31 a.m. June 26, 2014 - PR Newswire - PRF
Global Diabetic Retinopathy Market 2014-2018 12:22 p.m. June 25, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR Rx 7:00 a.m. June 24, 2014 - PR Newswire - PRF
Collaborations, FDA Clearances, and Technical Updates - Analyst Notes on Isis Pharmaceuticals, DexCom, Theravance Biopharma, Intrexon and Alere 5:30 a.m. June 19, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec 7:00 a.m. June 17, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sinopec Unveils Biodiversity Report at COP17

Sinopec's First Step on the Global Biodiversity Stage Seems like Sinopec (HKG: 0386) has decided to toss its hat into the biodiversity conservation ring. At COP17 in Armenia, they released their inaugural Global Biodiversity Conservation Report—an event that marks more than just a company selling oil and gas. Now, they're talking wildlife and ecologies. Is that irony,...

NumbersGame's Bold Integration Ups the Accounting Ante

Integrating the Heavy Hitters: Stripe, Square, and Ramp Diving headfirst into the mix, NumbersGame's recent move to open up integration with heavyweights like Stripe, Square, and Ramp is nothing short of a game-changer for accountants in the field. If you’re an accounting firm handling multiple clients, brace yourself—these latest enhancements might just redefine the...

Fresha Teams with Klarna: Shaking Up Beauty Payments

New Flexibility at the Beauty Checkout Hey, if you've ever paced back and forth considering signing up for that luxury self-care spree, well, Fresha’s latest move might just tip the scales. The beauty and wellness booking giant has partnered with Klarna, diving headfirst into the Buy Now, Pay Later (BNPL) craze. It's about time, right? Everyone loves a good spa session,...

Oracle's $20 Billion Offering: What Investors Need to Know

Oracle's Big Play: A $20 Billion Offering Nobody said playing in the big leagues was easy, and Oracle seems to be doubling down on that idea. Today, they spilled the beans on their ambition to rake in a cool $20 billion through an offering of common stock and senior notes. For those of us who keep a close eye on NYSE:ORCL, this is more than just a number—it's a signal...

TriMas Streamlines Portfolio with Rapak Sale

TriMas Sheds Rapak: A Strategic Move Here's a twist worth dissecting: TriMas Corporation (NASDAQ: TRS) has offloaded its subsidiary Rapak, LLC to the German industrial packaging giant, Ringmetall SE. This isn't just a business shuffle—it's a calculated pivot with eyes on sharpening the core business blade. As they announced from Bloomfield Hills, Michigan, this move...

Platinum Equity's Bold Move on Warren Valve: An Analysis

A Big Play in the Valve Game Straight out of the industrial playbook, Platinum Equity swoops in with its latest acquisition of Warren Valve, yanking it from the clutches of Allied Group. It's not every day you see a move like this in the flow control world. Yeah, you heard that right—flow control. The kind of business that’s all about ensuring the right stuff gets to...

Extreme Weather Survivors Rally for Change with 'Stolen Summers'

Lighting a Fire Under Complacency Elections often bring out the big dogs, but rarely do you see a grassroots campaign like Extreme Weather Survivors’ 'Stolen Summers' making such ripples. Rallying from New York to North Carolina and everywhere in between, this campaign has been a clarion call for communities ravaged by Mother Nature's fury. And let's face it, the...

Clarivate Integrates Trademark Data with Microsoft AI

You know, the market's all abuzz with AI this, AI that. But today, we're getting a glimpse at something that isn't just hyped-up vaporware; it's actually useful. Clarivate Plc (NYSE:CLVT), which has carved a niche in transformative intelligence, is teaming up with Microsoft to slide their CompuMark trademark data into Microsoft Copilot via something they call IPOne. It's...

Ascletis Showcases Bold Moves in Obesity Drug Arena

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

Immunic's November Moves: Conferences and Clinical Trials

Immunic Taps Into November Conferences Every now and then, you catch a company that's not just spinning its wheels but making some potentially big waves in their field. This time, it's Immunic, Inc. (Nasdaq: IMUX), stepping into the spotlight. They're strutting their stuff at several investor conferences this November, starting with Boston and New York, then hopping over...